RECENT NEWS

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment for hormone-sensitive prostate cancer patients.

The Department of Health and Social Care (DHSC) has appointed four experienced executive business leaders to strengthen partnerships with strategic suppliers to health.

Roche has announced plans to invest up to US $550 million in its diagnostics manufacturing site in Indianapolis by 2030.

The new headquarters of UK Biobank, a £60m state-of-the-art laboratory and innovation hub at Manchester Science Park called Greenheys, recently celebrated an important milestone, ‘topping out’ the new building.

A single blood test, designed to pick up chemical signals indicative of the presence of many different types of cancer, could thwart progression to advanced disease while the malignancy is still at an early stage and amenable to treatment in up to half of cases, suggests a new study.

Leica Microsystems has launched the Visoria series of upright microscopes, to help enhance the efficiency and comfort of routine microscopy work for pathologists, quality control managers, and researchers.

Histofy, a leading UK-based pathology AI company focused on accelerating histopathology workflows in both clinical and pharmaceutical sectors, has announced a strategic partnership with Source BioScience UK Limited, the largest histopathology service provider in the United Kingdom.

Chemists at Massachusetts Institute of Technology (MIT) have found a way to identify a complex sugar molecule in the cell walls of the bacteria that cause tuberculosis.

Genomics England has announced the appointment of Julian Thomas into the new role of Chief Technology and Product Officer.

The UK government has unveiled details of a new tool which it says will speed up cancer diagnosis and treatment, as part of its major reform to the NHS.

A new report published by the UK Health Security Agency (UKHSA) shows current state of health inequalities in England caused by infectious diseases, as well as environmental health hazards.

Molecular diagnostics firm Seegene has revealed some details of its forthcoming CURECA automated PCR system following its recent launch at the European Society of Clinical Microbiology and Infectious Diseases in Vienna, Austria.

Roche has announced the launch of its Elecsys PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients showing signs of metabolic dysfunction–associated steatotic liver disease (MASLD).

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a vaccine (Vimkunya) used to prevent disease caused by the chikungunya virus in people 12 years of age and older.

Plans to create the London Cancer Hub, set to be the world’s leading district for cancer research and treatment submitted to Sutton Council. Once built the new centre will create thousands of jobs and contribute £1.2 billion to the UK economy.

IBMS, BD and PLMR Healthcomms have released a new report which highlights the need for more consistent and collaborative approaches to reduce contamination rates, improve diagnostic accuracy and enhance patient care.

BioSkryb Genomics and Tecan Group have introduced a high-throughput single-cell workflow, combining BioSkryb’s 384-well format of the ResolveOME Whole Genome and Transcriptome Single-Cell Core Kit with the Uno Single Cell Dispenser, provided by Tecan.

IBMS, LabMed and RCPath have collaborated to set out a shared position on how UK laboratories can improve oversight, clarify accountability and take a whole-system approach to managing assay performance.

Research scientists have identified five specific blood proteins that can accurately predict a person’s risk for developing a serious form of liver disease as early as 16 years before they experience symptoms, enabling early intervention and possible prevention and treatment, according to a study to be presented at Digestive Disease Week.

A groundbreaking UK research network has been launched to uncover how gut health influences the brain, immune system and mental wellbeing. The project will run for four years and has received £4.5 million in funding from the Biotechnology and Biological Sciences Research Council (BBSRC).